Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


MDC collaboration partner Formula Pharmaceuticals completes merger with CoImmune

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

The alliance that had been closed in 2015 with the support of Ascenion, aims to develop the company’s unique CAR-CIK technology in combination with the MDC’s proprietary Sleeping Beauty (SB) gene transfer system for the immunotherapy of cancer. The approach has the potential to overcome commercial limitations related to existing CAR-T therapies by allowing production from allogeneic donors for an off-the-shelf product, non-viral gene transfer, multifunctional 'killing' mechanisms and enhanced safety based on prior clinical data. The merger was accompanied by a $6 million lead investment in CoImmune's series A financing to fund the CAR-CIK program.


Further information:

See CoImmune’s press release